Randomized, double-blind study of the clinical efficacy of 3 days of azithromycin compared with co-amoxiclav for the treatment of acute otitis media

Background: Compared with 5 days of dosing, a 3 day dosing regimen of azithromycin for treatment of acute otitis media (AOM) may improve compliance, will simplify therapy for the caregiver and, by giving the same total dose as the 5 day regimen, provide more drug when the bacterial burden is highest...

Full description

Saved in:
Bibliographic Details
Published in:Journal of antimicrobial chemotherapy 2003-09, Vol.52 (3), p.469-472
Main Authors: Dunne, Michael W., Latiolais, Thomas, Lewis, Barnett, Pistorius, Bruce, Bottenfield, Gerald, Moore, William H., Garrett, Anne, Stewart, Tracy D., Aoki, Jeffrey, Spiegel, Craig, Boettger, David, Shemer, Anne
Format: Article
Language:English
Subjects:
Acute Disease
Amoxicillin-Potassium Clavulanate Combination - adverse effects
Amoxicillin-Potassium Clavulanate Combination - therapeutic use
Anti-Bacterial Agents - adverse effects
Anti-Bacterial Agents - therapeutic use
Antibacterial agents
Antibiotics. Antiinfectious agents. Antiparasitic agents
AOM
Azithromycin - adverse effects
Azithromycin - therapeutic use
Biological and medical sciences
Child, Preschool
children
Double-Blind Method
Drug Therapy, Combination - adverse effects
Drug Therapy, Combination - therapeutic use
Female
Hearing Tests
Humans
Infant
Male
Medical sciences
Otitis Media - drug therapy
Otitis Media - pathology
Pharmacology. Drug treatments
Treatment Outcome
Tympanic Membrane - pathology
tympanic membrane disease
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background: Compared with 5 days of dosing, a 3 day dosing regimen of azithromycin for treatment of acute otitis media (AOM) may improve compliance, will simplify therapy for the caregiver and, by giving the same total dose as the 5 day regimen, provide more drug when the bacterial burden is highest. Methods: Children of 6 months–12 years were enrolled if they had had symptoms and signs of AOM for
ISSN:0305-7453
1460-2091
1460-2091
DOI:10.1093/jac/dkg358